Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Fixed-duration epcoritamab plus R 2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Blood (2025) 146 (22): 2629–2640.

https://doi.org/10.1182/blood.2025029909

Published: 2025

Includes: Supplemental data

Journal Articles

Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety

Umberto Vitolo, Lorenzo Falchi, Sylvia Snauwaert, Fritz Offner, Marcel Nijland, Per-Ola Andersson, Poliana Patah, Isil Altintas, Jennifer Marek, Malene Risum, Yi Hao, Joshua Brody

Blood (2025) 146 (Supplement 1): 5357.

https://doi.org/10.1182/blood-2025-5357

Published: 2025

Journal Articles

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Blood (2025) 146 (Supplement 1): 466.

https://doi.org/10.1182/blood-2025-466

Published: 2025

Journal Articles

BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with Relapsed/Refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the Phase 1 dose escalation study

Blood (2025) 146 (Supplement 1): 480.

https://doi.org/10.1182/blood-2025-480

Published: 2025

Journal Articles

Longitudinal circulating tumor DNA dynamics during & after first-line therapy in a national cohort of large B-cell lymphomas

Blood (2025) 146 (Supplement 1): 474.

https://doi.org/10.1182/blood-2025-474

Published: 2025

Journal Articles

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Kim Linton, Franck Morschhauser, Marcel Nijland, Huiqiang Huang, John Seymour, Catherine Thieblemont, Abualbishr Alshreef, Jennifer Lord-Bessen, Rajesh Kamalakar, Zhijie Ding, Gauri Sunkersett, Jian Mei, Lorenzo Falchi

Blood (2025) 146 (Supplement 1): 5370.

https://doi.org/10.1182/blood-2025-5370

Published: 2025

Journal Articles

Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population

Joshua Brody, David Belada, Daniel Morillo, Régis Costello, Marek Trneny, Sven de Vos, Gerardo Musuraca, Umberto Vitolo, David Lewis, Jacob Christensen, Marcel Nijland, Tony Jiang, Kubra Karagoz, Andrew J. Steele, Jennifer Marek, Liwei Wang, Malene Risum, Raul Cordoba, Judit Jørgensen

Blood (2025) 146 (Supplement 1): 3736.

https://doi.org/10.1182/blood-2025-3736

Published: 2025

Journal Articles

Spatial anatomical genomic heterogeneity and aberrant somatic hypermutation define clonal evolution pathways that predict treatment resistance in aggressive B-cell lymphomas

Jordan Goldstein, Steven Wang, Benoit Tessoulin, Chih Long Liu, Florian Scherer, Steven Le Gouill, Martine Chamuleau, Marcel Nijland, Maximilian Diehn, David Kurtz, Ash Alizadeh

Blood (2025) 146 (Supplement 1): 354.

https://doi.org/10.1182/blood-2025-354

Published: 2025

Journal Articles

Immunosuppressed Tumor Microenvironment in MYC -Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Blood (2024) 144 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2024-205968

Published: 2024

Journal Articles

Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1588.

https://doi.org/10.1182/blood-2024-206636

Published: 2024

Journal Articles

Dynamics of Circulating Tumor DNA in Relapsed/Refractory DLBCL Patients

Yujie Zhong, Johanna Bult, Nick Veltmaat, Filipe Montes de Jesus, Diana Al-Sarayfi, Anke Van Den Berg, Joost L. Kluiver, Wouter Plattel, Arjan Diepstra, Marcel Nijland

Blood (2024) 144 (Supplement 1): 6198.

https://doi.org/10.1182/blood-2024-203072

Published: 2024

Journal Articles

Molecular Profiling and Disease Tracking of Post-Transplant Lymphoproliferative Diseases Using Cell-Free DNA

Nick Veltmaat, Yujie Zhong, Filipe Montes De Jesus, Johanna Bult, Pim Mutsaers, Wendy B.C. Stevens, Rogier Mous, Marjolein W.M. van der Poel, Martine E.D. Chamuleau, Walter Noordzij, Erik A.M. Verschuuren, Joost L. Kluiver, Arjan Diepstra, Wouter Plattel, Anke van den Berg, Marcel Nijland

Blood (2024) 144 (Supplement 1): 6234.

https://doi.org/10.1182/blood-2024-210000

Published: 2024

Journal Articles

Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders

Blood (2024) 144 (Supplement 1): 648.

https://doi.org/10.1182/blood-2024-206532

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3

Joshua Brody, Lorenzo Falchi, Umberto Vitolo, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Poliana Patah, Jennifer Marek, Christopher Morehouse, Andrew J. Steele, Yi Hao, Daniela Hoehn, Kim Linton

Blood (2024) 144 (Supplement 1): 1627.

https://doi.org/10.1182/blood-2024-200369

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Blood (2024) 144 (Supplement 1): 342.

https://doi.org/10.1182/blood-2024-200262

Published: 2024

Journal Articles

Unveiling Transformation Mechanisms of Nodal Marginal Zone Lymphoma Using a Multi-Omics Approach

Johanna A.A. Bult, Yujie Zhong, Fleur A. De Groot, Ruben A.L. De Groen, Nick Veltmaat, Diana Al-Sarayfi, Wouter Plattel, Joost L. Kluiver, Anke Van Den Berg, Stefano Rosati, Arjan Diepstra, Joost S.P. Vermaat, Marcel Nijland

Blood (2024) 144 (Supplement 1): 2984.

https://doi.org/10.1182/blood-2024-206997

Published: 2024

Journal Articles

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Blood (2023) 142 (Supplement 1): 3090.

https://doi.org/10.1182/blood-2023-181707

Published: 2023

Journal Articles

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Blood (2023) 142 (Supplement 1): 858.

https://doi.org/10.1182/blood-2023-173953

Published: 2023

Journal Articles

Patients with Relapsed Large B-Cell Lymphoma after 12 Months Have a Similarly Poor Prognosis As Patients with a Relapse before 12 Months

Hilde T Van Der Galien, Hilde AM Kooistra, Robby Kibbelaar, Nic JGM Veeger, Marcel Nijland, Geert A. Huls, Tom Van Meerten, Rozemarijn S Van Rijn

Blood (2023) 142 (Supplement 1): 444.

https://doi.org/10.1182/blood-2023-185993

Published: 2023

Journal Articles

No Discernable Dysfunction of Peripheral T-Cells and NK-Cells Despite Distinct Phenotypes in MYC Rearranged Versus Non Rearranged B-Cell Lymphoma Patients

A. Vera de Jonge, Carolien Duetz, Wassilis S.C Bruins, Charlotte L.B.M. Korst, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Marcel Nijland, Marjolein Van Der Poel, Koen de Heer, Clara Klerk, Leonie Strobbe, Margriet Oosterveld, Rinske Boersma, Harry R. Koene, Erik van Werkhoven, Martine E.D. Chamuleau, Tuna Mutis

Blood (2023) 142 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2023-180734

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Fixed-duration epcoritamab plus R 2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with Relapsed/Refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the Phase 1 dose escalation study

Longitudinal circulating tumor DNA dynamics during & after first-line therapy in a national cohort of large B-cell lymphomas

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population

Spatial anatomical genomic heterogeneity and aberrant somatic hypermutation define clonal evolution pathways that predict treatment resistance in aggressive B-cell lymphomas

Immunosuppressed Tumor Microenvironment in MYC -Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma

Dynamics of Circulating Tumor DNA in Relapsed/Refractory DLBCL Patients

Molecular Profiling and Disease Tracking of Post-Transplant Lymphoproliferative Diseases Using Cell-Free DNA

Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders

Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Unveiling Transformation Mechanisms of Nodal Marginal Zone Lymphoma Using a Multi-Omics Approach

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Patients with Relapsed Large B-Cell Lymphoma after 12 Months Have a Similarly Poor Prognosis As Patients with a Relapse before 12 Months

No Discernable Dysfunction of Peripheral T-Cells and NK-Cells Despite Distinct Phenotypes in MYC Rearranged Versus Non Rearranged B-Cell Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only